| Patent Number |
Title Of Patent |
Date Issued |
| 7439347 |
Hepatitis C virus non-structural NS3/4A fusion gene |
October 21, 2008 |
| Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptid |
| 7335359 |
Glycosylated specificity exchangers |
February 26, 2008 |
| The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described |
| 7332166 |
Glycosylated specificity exchangers |
February 19, 2008 |
| The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described |
| 7318926 |
Glycosylated specificity exchangers |
January 15, 2008 |
| The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described |
| 7307066 |
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
December 11, 2007 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as m |
| 7261883 |
Vaccines containing ribavirin and methods of use thereof |
August 28, 2007 |
| The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antige |
| 7244715 |
Vaccines containing ribavirin and methods of use thereof |
July 17, 2007 |
| Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus |
| 7244422 |
Vaccines containing ribavirin and methods of use thereof |
July 17, 2007 |
| The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of Ribavirin as an adjuvant to a vaccine protocol and compositions having Ribavirin and an antige |
| 7241440 |
Vaccines containing ribavirin and methods of use thereof |
July 10, 2007 |
| Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus |
| 7226912 |
Hepatitis C virus non-structural NS3/4A fusion gene |
June 5, 2007 |
| Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the invention include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptid |
| 7223743 |
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
May 29, 2007 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as m |
| 7022830 |
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
April 4, 2006 |
| Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as m |
| 7019111 |
Glycosylated ligand/receptor specificity exchangers specific for bacterial adhesion receptors |
March 28, 2006 |
| The present invention generally relates to compositions and methods for preventing and treating human diseases including, but not limited to, pathogens such as bacteria, yeast, parasites, fungus, viruses, and cancer. More specifically, embodiments described herein concern the manufac |
| 7012129 |
Antiviral composition comprising glycine amide |
March 14, 2006 |
| Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said tripeptide amides and/or glycine amide and methods of us |
| 6960569 |
Hepatitis C virus non-structural NS3/4A fusion gene |
November 1, 2005 |
| Disclosed herein is the discovery of a novel hepatitis C virus (HCV) isolated from a human patient. Embodiments of the inevntion include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, |
| 6933366 |
Specificity exchangers that redirect antibodies to bacterial adhesion receptors |
August 23, 2005 |
| Specificity exchangers and methods of making and using specificity exchangers are disclosed. Specificity exchangers are useful for preventing and treating human diseases including cancer and those resulting from pathogens such as bacteria, yeast, parasites, fungus, viruses, and the l |
| 6858590 |
Vaccines containing ribavirin and methods of use thereof |
February 22, 2005 |
| Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising ribavirin and an antigen, preferably an antigen that has an epitope present in Hepatitis C virus |
| 6660842 |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen |
December 9, 2003 |
| The present invention generally relates to compositions and methods for preventing and treating human diseases including, but not limited to, pathogens such as bacteria, yeast, parasites, fungus, viruses, and cancer. More specifically, embodiments described herein concern the manufacture |
| 6593455 |
Tripeptide amides that block viral infectivity and methods of use thereof |
July 15, 2003 |
| Embodiments relate to the discovery that tripeptide amides, which correspond to viral capsid sequences, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising tripeptide amides and methods of using sai |
| 6537967 |
Pentamer peptide amide, ALGPGNH2, which inhibits viral infectivity and methods of use thereof |
March 25, 2003 |
| The present invention relates to the discovery that a specific pentamer peptide amide, which corresponds to a viral capsid sequence, can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More specifically, medicaments comprising said pentamer pep |
| 6417324 |
Synthetic peptides that bind to the hepatitis B virus core and e antigens |
July 9, 2002 |
| The present invention relates generally to the field of virology. More particularly, the invention relates to the discovery that peptides, which bind to the Hepatitis B virus (HBV) core and e antigens, can be used to inhibit HBV infection. Embodiments concern "binding partners", which |
| 5869232 |
Antigen/antibody specificity exchanger |
February 9, 1999 |
| An antigen/antibody specificity exchanger is disclosed. It comprises: A) an amino-acid sequence corresponding to an amino-acid sequence of an antibody which specifically binds to a certain antigen, including hapten, B) linked by a link to C) an amino-acid sequence to which a certain anti |
